SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 278 filers reported holding SAGE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $444,000 | -23.3% | 3,164 | 0.0% | 0.02% | -21.1% |
| Q2 2019 | $579,000 | +20.4% | 3,164 | +4.6% | 0.02% | +11.8% |
| Q1 2019 | $481,000 | +90.9% | 3,024 | +14.9% | 0.02% | +70.0% |
| Q4 2018 | $252,000 | -36.2% | 2,632 | -6.0% | 0.01% | -23.1% |
| Q3 2018 | $395,000 | +348.9% | 2,800 | +400.0% | 0.01% | +333.3% |
| Q2 2018 | $88,000 | +2100.0% | 560 | +1900.0% | 0.00% | – |
| Q1 2018 | $4,000 | – | 28 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |